Clinical trial demonstrates a 40% objective tumor response from erdafitinib in advanced FGFR-altered urothelial carcinoma, highlighting its therapeutic potential despite frequent adverse events.
The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations. Treatment-related grade 3 or higher adverse events were reported in nearly half the patients. (Funded by Janssen Research and Development; BLC2001 ClinicalTrials.gov number, NCT02365597.).
No takes yet. Share an insight, caveat, or question.
Loriot et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: